ASH 2024丨Dr. Jing Pan: Applications of CAR-T Therapy in R/R T-ALL and B-ALL, Prognostic Factors, and a Stratified CAR-T Treatment Framework

ASH 2024丨Dr. Jing Pan: Applications of CAR-T Therapy in R/R T-ALL and B-ALL, Prognostic Factors, and a Stratified CAR-T Treatment Framework

2024.12.31
The 66th American Society of Hematology (ASH) Annual Meeting was held in San Diego, USA, from December 7–10, 2024. Renowned as the largest and most comprehensive international academic event in the field of hematology, the conference gathers leading experts and researchers worldwide to discuss and exchange groundbreaking advancements in hematology. At this year's meeting, the research led by Dr. Jing Pan from Beijing GoBroad Boren Hospital garnered significant attention, with two studies related to CAR-T therapy (abstracts 964 and 3466) being featured. To provide a deeper understanding of these pivotal findings, Hematology Frontier interviewed Dr. Jing Pan, who shared insights on these studies and the broader topic of CAR-T therapy. Below is a summary of the research and interview.
Professor Dingwei Ye: Advancing Innovation in Uro-Oncology from Bench to Bedside, Sharing Chinese Expertise to Benefit Global Patients

Professor Dingwei Ye: Advancing Innovation in Uro-Oncology from Bench to Bedside, Sharing Chinese Expertise to Benefit Global Patients

2024.12.30
In recent years, breakthroughs in basic research and clinical trials, particularly in combined targeted and immunotherapy strategies and the development of domestically produced novel drugs, have significantly advanced clinical practices in uro-oncology. However, transforming cutting-edge research into practical clinical applications and sharing Chinese expertise with international patients remains an ongoing challenge. The 14th Shanghai Genitourinary Oncology Academic Conference and Annual Meeting of Chinese Anti-Cancer Association—Genitourinary Oncology Committee (CACA-GO) were held in Shanghai from December 6 to 8. Following the event, Urology Frontier invited Professor Dingwei Ye, the conference chair and leading expert from Fudan University Shanghai Cancer Center, to share the highlights and experiences of this impactful event.
ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL

ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL

2024.12.30
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the lymphoma field witnessed several pivotal study outcomes. Oncology Frontier - Hematology Frontier invited Dr. Jun Shi from The Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, to provide a detailed analysis and commentary on two highly impactful studies presented during the meeting.
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)

ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)

2024.12.30
Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in San Diego, numerous studies on MDS were presented, showcasing significant progress in the treatment and prognostic evaluation of low-risk MDS. Oncology Frontier - Hematology Frontier invited Dr. Huaquan Wang from Tianjin Medical University General Hospital to provide expert commentary on the most impactful research in this field, delivering cutting-edge insights to our readers.
ASH 2024 | Dr. Wenming Chen Discusses Key Myeloma Research

ASH 2024 | Dr. Wenming Chen Discusses Key Myeloma Research

2024.12.30
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely updates on the most significant developments at the conference, Oncology Frontier - Hematology Frontier launched the "ASH Daily News Highlights" series. Dr. Jun Zhu from Peking University Cancer Hospital serves as the series host, connecting daily with onsite experts to bring firsthand updates. On the third day of the conference, we were honored to hear from Dr. Wenming Chen of Beijing Chaoyang Hospital, who shared insights into key studies in the field of myeloma.
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 1)

ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 1)

2024.12.29
Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 7th to 10th, numerous studies in the field of MDS were announced, with significant progress particularly in the treatment and prognosis assessment of low-risk MDS. "Hematology Frontier" specially invited Dr. Huaquan Wang from the Department of Hematology, Tianjin Medical University General Hospital, to select and comment on the key studies, in hopes of bringing cutting-edge information and unique insights to everyone.
ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)

ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)

2024.12.29
Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some research results on prognostic factors of CLL were announced. "Hematology Frontier" specially invited Dr. Shenmiao Yang from the Peking University Institute of Hematology, to select key studies from the conference and provide insightful commentary, aiming to offer valuable references and insights to colleagues in the field.
ASH 2024 | Dr. He Huang’s Team Advances Breakthroughs in Bone Marrow Transplantation and Cellular Immunotherapy

ASH 2024 | Dr. He Huang’s Team Advances Breakthroughs in Bone Marrow Transplantation and Cellular Immunotherapy

2024.12.28
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, had 20 studies selected for presentation, including eight as oral presentations. Their achievements not only highlighted their exceptional contributions but also delivered valuable research findings and innovative strategies to the global academic community.